Glutamate receptor trafficking: endoplasmic reticulum quality control involves ligand binding and receptor function.
The glutamate receptor (GluR) agonist-binding site consists of amino acid residues in the extracellular S1 and S2 domains in the N-terminal and M3-M4 loop regions, respectively. In the present study, we sought to confirm that the conserved ligand-binding residues identified in the AMPA receptor S1S2 domains also participate in ligand binding of GluR6 kainate receptors. Amino acid substitutions were made in the GluR6 parent at R523, T690, and E738 to alter their potential interactions with ligand. Mutant receptors were expressed in human embryonic kidney 293 cells, confirmed by Western blot analysis, and tested by [3H]kainate binding and patch-clamp recording. Each of the binding site mutations was sufficient to reduce [3H]kainate binding to undetectable levels and eliminate functional responses to glutamate or kainate. As with our studies of other nonfunctional mutants (Fleck et al., 2003), immunocytochemical staining and cell-surface biotinylation studies showed that the mutant receptors were retained intracellularly and did not traffic to the cell surface. Endoglycosidase-H digests and colocalization with endoplasmic reticulum (ER) markers demonstrated that the mutant receptors are immaturely glycosylated and retained in the ER. Immunoprecipitation, native PAGE, and functional studies confirmed that the GluR6-binding site mutants are capable of multimeric assembly, indicating their retention in the ER does not result from a gross protein folding error. Together, these results confirm the role of R523, T690, and E738 directly in ligand binding to GluR6 and further support our previous report that nonfunctional GluRs are retained intracellularly by a functional checkpoint in ER quality control.
Mah
Stephanie J
SJ
Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, New York 12208, USA.
Cornell
Elizabeth
E
Mitchell
Nicholas A
NA
Fleck
Mark W
MW
D019943:Amino Acid Substitution / Q000502:physiology; D001665:Binding Sites / Q000502:physiology; D019921:Biotinylation / Q000379:methods; D015153:Blotting, Western / Q000379:methods; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004558:Electric Stimulation / Q000379:methods; D004721:Endoplasmic Reticulum / Q000502:physiology*; D015870:Gene Expression / Q000235:genetics; D018698:Glutamic Acid / Q000494:pharmacology; D006031:Glycosylation / Q000187:drug effects; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D047468:Immunoprecipitation / Q000379:methods; D007608:Kainic Acid / Q000493:pharmacokinetics; D008024:Ligands; D008164:Luminescent Proteins; D017038:Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase / Q000494:pharmacology; D008564:Membrane Potentials / Q000235:genetics / Q000528:radiation effects; D018613:Microscopy, Confocal / Q000379:methods; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed / Q000379:methods; D009154:Mutation / Q000502:physiology; D018408:Patch-Clamp Techniques / Q000379:methods; D043524:Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase / Q000494:pharmacology; D011485:Protein Binding / Q000235:genetics / Q000502:physiology; D021381:Protein Transport / Q000502:physiology*; D011869:Radioligand Assay / Q000379:methods; D018091:Receptors, AMPA / Q000737:chemistry / Q000378:metabolism; D018092:Kainic Acid Receptors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D016415:Sequence Alignment / Q000379:methods; D013329:Structure-Activity Relationship; D014162:Transfection / Q000379:methods; D014316:Tritium / Q000493:pharmacokinetics; D000097806:GluK2 Kainate Receptor
D018698:Glutamic Acid; D007608:Kainic Acid; D008024:Ligands; D008164:Luminescent Proteins; D017038:Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase; D043524:Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; D018091:Receptors, AMPA; D018092:Kainic Acid Receptors; D014316:Tritium; D000097806:GluK2 Kainate Receptor; C104722:glutamate receptor ionotropic, AMPA 2
Pharmacol Rev. 1999 Mar;51(1):7-61
10049997
Neuron. 1999 Mar;22(3):537-48
10197533
J Biol Chem. 1999 Jun 11;274(24):16907-16
10358037
J Neurosci. 1999 Sep 15;19(18):7781-92
10479681
Science. 1999 Dec 3;286(5446):1882-8
10583943
J Biol Chem. 1999 Dec 24;274(52):37210-8
10601284
Neuron. 2000 Jan;25(1):177-90
10707982
J Biol Chem. 2000 Jul 14;275(28):21355-63
10748170
J Clin Invest. 2000 Apr;105(7):887-95
10749568
Neuron. 2000 Jul;27(1):97-106
10939334
Pflugers Arch. 2000 Jul;440(3):481-7
10954336
Nat Neurosci. 2000 Oct;3(10):992-7
11017171
Neuron. 2000 Oct;28(1):165-81
11086992
J Neurosci. 2001 Feb 15;21(4):1189-202
11160389
J Neurosci. 2001 Feb 15;21(4):1203-10
11160390
Neuron. 2000 Dec;28(3):887-98
11163274
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2431-6
11226256
J Biol Chem. 2001 May 25;276(21):18384-91
11279119
J Neurosci. 2001 May 1;21(9):3063-72
11312291
Neuron. 2001 Jul 19;31(1):103-13
11498054
Endocrinology. 2001 Sep;142(9):3926-34
11517171
Annu Rev Physiol. 2002;64:19-46
11826262
EMBO J. 2002 Apr 2;21(7):1628-37
11927547
Mol Pharmacol. 2002 May;61(5):1070-80
11961124
J Neurosci. 2002 May 1;22(9):3392-403
11978816
Curr Opin Neurobiol. 2002 Jun;12(3):287-92
12049935
Neuron. 2002 May 16;34(4):589-98
12062042
J Biol Chem. 2002 Nov 1;277(44):41940-7
12167621
Mol Cell Neurosci. 2002 Sep;21(1):38-50
12359150
Eur J Biochem. 2002 Dec;269(24):6261-70
12473122
J Neurosci. 2003 Feb 15;23(4):1219-27
12598610
Nat Rev Mol Cell Biol. 2003 Mar;4(3):181-91
12612637
Nat Rev Neurosci. 2003 Jun;4(6):481-95
12778120
EMBO J. 2003 Jun 16;22(12):2873-85
12805203
Biochem Soc Trans. 2003 Aug;31(Pt 4):865-8
12887323
Neuron. 1992 Feb;8(2):257-65
1371217
EMBO J. 1992 Apr;11(4):1651-6
1373382
FEBS Lett. 1992 Aug 24;308(3):253-7
1380467
Neuropharmacology. 2003 Nov;45(6):768-76
14529715
Neuron. 2003 Oct 9;40(2):265-76
14556708
Annu Rev Cell Dev Biol. 2003;19:649-76
14570585
Ann N Y Acad Sci. 2003 Sep;998:66-80
14592864
J Biol Chem. 2004 Mar 19;279(12):11096-105
14707124
J Neurosci. 2004 Jan 21;24(3):679-91
14736854
J Biol Chem. 2004 Mar 12;279(11):9673-6
14742424
J Biol Chem. 2005 Feb 18;280(7):6085-93
15583001
Neuroscience. 1989;33(1):157-67
2574834
Neuron. 1994 Dec;13(6):1345-57
7527641
Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):13018-22
7528929
Neuron. 1995 Aug;15(2):453-62
7646897
Trends Neurosci. 1993 Sep;16(9):359-65
7694406
J Cell Biol. 1995 May;129(4):971-8
7744968
J Neurochem. 1977 Jan;28(1):149-58
833589
J Biol Chem. 1996 Jun 28;271(26):15299-302
8663365
Neuron. 1996 Nov;17(5):979-90
8938129
Annu Rev Cell Dev Biol. 1996;12:27-54
8970721
J Pharmacol Exp Ther. 1997 Jan;280(1):422-7
8996224
Neuron. 1997 Mar;18(3):493-503
9115742
Brain Res Mol Brain Res. 1997 Jul;47(1-2):339-44
9221933
Mol Pharmacol. 1997 Nov;52(5):861-73
9351977
J Neurosci. 1998 Jan 15;18(2):581-9
9425000
Biochem J. 1998 Mar 15;330 ( Pt 3):1461-7
9494120
Endocr Rev. 1998 Apr;19(2):173-202
9570036
Science. 1998 Jun 5;280(5369):1596-9
9616121
Brain Res Brain Res Rev. 1998 May;26(2-3):217-29
9651532
EMBO J. 1998 Aug 17;17(16):4704-11
9707429
Bioessays. 1998 Jul;20(7):546-54
9723003
Nature. 1998 Oct 29;395(6705):913-7
9804426